s2wR from ISC in FDA approach [General Sta­tis­tics]

posted by d_labes  – Berlin, Germany, 2017-03-05 12:18 (1736 d 11:45 ago) – Posting: # 17135
Views: 15,671

Dear ElMaestro!

» ...
» » Moreover the FDA evaluation uses intra-subject constrasts to evaluate s2wR
» What does this mean? Don't you usually get it from the REML covarance matrix?

If you have a look at the SAS code in the progesterone guidance you will discover that s2wR is not obtained from the REML covariance matrix but rather from an ISC evaluation. Means you calculate R-R within the subjects and use that difference in an ANOVA with the sequence as the soley effect.
The REML estimates don't play a role, since a mixed model only comes into the play if CVwR is <=30% and conventional ABE has to be used. Here you may get s2wR from the REML covariance matrix but it is not used in ABE.
That's one of the curiosities of the FDA approach, among others.

» I think EMA's approach can be condensed into intra-Subject contrasts to derive S2wR from completers.

Here you err. The EMA approach calls for an evaluation via lm(), GLM or comparable using the R(eference) data only with the effects period and subject (sequence may be also included but doesn't change the estimate of s2wR). This gives some different results to an estimation via ISC as described above. Try it.

BTW: Have a look into Implementation_scaledABE_sims.pdf in the doc subdirectory of R package PowerTOST. There you will find a cookbook manner description of the computations involved in the EMA or FDA approaches for scaled ABE.



Complete thread:

 Admin contact
21,785 posts in 4,556 threads, 1,547 registered users;
online 9 (0 registered, 9 guests [including 2 identified bots]).
Forum time: Monday 00:04 CET (Europe/Vienna)

The history of statistics is like a telephone directory:
the plot is boring, full of numbers and the cast is endless.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz